Market Analysis - Cell Therapy And Molecular Medicine 2017
America Cell Therapy and Molecular Medicine Market Analysis and Reports | USA Conference Series
Cell therapy market investigation provides information about generally accepted clinical and analytical methods that are currently in use for applying cell therapy techniques. In 2015 cell-based market was analysed and projected to 2025 on the basis of therapeutic categories, technologies and geographical areas. The Autologous Stem Cell Therapy technology is changing the medical treatments by introducing various new therapies. The global market set up ACT is around $650 million in 2011 and anticipated to reach $2.2 billion by 2017 with growing at a CAGR of 21%. The global Stem Cell Therapy market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020. The global cell-based assays market is expected to reach USD 18,329.37 Million by 2020 from USD 10,799.53 Million in 2015, growing at a CAGR of 11.16% between 2015 and 2020.
On geographical perspective, global market is segmented into North America, Europe, Asia and Rest of the World (RoW). North America mainly dominates the global stem cell therapy market due to increased activities on stem cells. United States represents the largest market for stem cell therapy followed by Canada in North America. For the past five years the investment activities are actively being conducted in research and developments, hence attracting interests of cell therapy industry firms, academic institutions and medical centres. More than 500 companies involved in cell therapy of these companies, 170 are involved in stem cells. 72 academic institutions in the US involved in cell therapy along with their commercial collaborations.
Cell therapy technologies involves in gene therapy, drug delivery, cancer vaccines, tissue engineering and regenerative medicine. Regenerative medicines restore the functionality of cells & tissues and use to treat many degenerative disorders like neurodegenerative diseases, cardiovascular, dermatology and orthopaedic applications. Utilization of Nano materials in wound care, drug delivery, and immunomodulation creates new growth avenues for the regenerative medicines market. The global market size for regenerative medicine is expected to reach USD 49.41 billion by 2021 at a CAGR of 23.7% during the forecast period of 2016 to 2021. Moreover, the investments done by biotechnology and pharmaceutical companies in the field of regenerative medicines especially in cell therapies and immunotherapy, adds to the growth of market. There is a rapid increase in the need for organ transplantation and initiatives taken by the government has enhanced the regenerative medicine market growth. Followed by U.S, Europe is the second largest market for regenerative medicines with Germany leading the market in the region.
The tissue engineering and cell therapy products market is set to grow from a respectable $8.3 billion in 2010 to nearly $32 billion by 2018.
Figure 1:- Market size for types of Cancer Gene Therapy in USD Millions (2014-2018)
Figure 2:- Global Tissue Engineering and Cell Therapy Market by region (2014- 2017)
The gene therapy market is mainly dominated by oncology applications, with several companies and academic institutions targeting on novel and ‘difficult to treat’ cancers. Other therapeutic areas seeking developments in gene therapy includes cardiovascular diseases, monogenic diseases, inherited diseases, infectious diseases and neurological diseases. North America dominates to have the maximum number of clinical trials in gene therapy. This becomes the major reason for prevalent position of North America in gene therapy market.
The Cancer gene therapy is one of the upcoming and essential gene and cellular therapy resource for cancer researchers and clinicians. Global Market size was USD 805.5 million in 2015, with 20.7% CAGR estimation from 2016 to 2024. Some of the factors that has driven the global cancer gene therapy market over the forecast period includes the rapid technological advancements, increased adoption of emerging genomic technologies such as NGS (Next generation sequencing) and high density micro array. Due to the rising number of cases for cancer, the demand for gene therapy industry is expected to increase. By around 2021, this market hits at least $10 billion in sales, creating a booming market for the industrial big manufacturing equipment based upon projections that the number of patients treated with engineered cancer-fighting T-cells.
T-cells engineering involves extracting T-cells them from white blood cells (WBCs), genetically modifying them to target cancer cells and multiplying them in a bioreactor before re-injecting into patients. Therapies of this kind are developed by leading companies which include Novartis AG, Kite Pharma Inc., Juno Therapeutics Inc., Cellectis SA and Adaptimmune Therapeutics Plc. There are some big companies that functions as major players like SiBiono, Shanghai Sunway Biotech company limited, Altor Bioscience Corporation, Amgen, Aduro Biotech, BioCancell, OncoGeneX, New Link Genetics, ZioPharm and some others. The global cancer gene therapy market is dominated by small biotech firms and the players are constantly involved in R&D in order to treat life threatening diseases by developing novel methods.
As opportunities in basic research and drug discovery are big and growing very rapidly, the emerging economies are making huge investments in R&D. It is the fastest growing area of the industry. As compared to developed countries, the demand for life science products in emerging Asian nations such as China and India is growing at a robust rate. There are top leaders in cell-based assays market that include Becton, Merck & Co, Inc. (U.S.), Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), DiscoveRx (U.S.), Cell Signalling Technology, Inc. (U.S.), Cisbio Bioassays (France), Promega Corporation (U.S.) and General Electric Company (U.S.).
Moreover, the favourable regulations from government will enhance the cancer genetics industry growth. For example, Mainstreaming Cancer Genetics (MCG) programme aims to develop clinical infrastructure, information, assays, assessment and education that will allow gene testing of patients.
All over 20% growth is forecasted for the use of Adenoviral vectors in gene replacement approaches, gene-based immunotherapy, syndicate gene with chemotherapy and suicide gene. Therefore retroviral vectors can be applied to permanently modify the host cell nuclear genome, and it’s oncolytic actions are mainly through the stimulation of immune system. This segment will grow at 20.6% CAGR over the forecast period. The market for cancer gene induced immunotherapy is accounted for 14% of the revenue share in 2015, and forecasted to exceed USD 592.7 million by 2024.
The global bioinformatics market is expected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, hence growing at a CAGR of 21.1% during the forecast period. The bioinformatics market is broadly segmented on the basis of sector, services, products, region and application. On the basis of sector this market is divided into molecular medicine, forensic, agriculture, animal, research and gene therapy. Among these, molecular medicine and gene therapy has reached the largest share in 2016 bioinformatics market. North America has the largest share of bioinformatics market in 2016 due to increasing demand for technological advancements, demand for bioinformatics across genomics and proteomics research, and research institutes enhancing the growth of market.
Conferenceseries welcomes you to attend the Annual Summit on Cell Therapy during September 27-28, 2017 at Chicago, USA. We cordially invite all the participants from all over the world who are interested in sharing their knowledge and research in the arena of Cell & Gene Therapy. The theme of Annual Summit on Cell therapy is "Benefits of Cell and Gene Therapy on Human Health" which provides a unique way to present the evidences on latest advancements and researches with a holistic approach to different areas of interest. The conference tracks are designed in such a way to cover all the areas of researches involved with Cell and Gene therapy and their impacts on human health. The main aim of this conference is to provide a platform to all the Scientists, Doctors, Medical professionals, Business delegates who will undoubtedly enhance the conference by giving their views regarding latest advancements to all the attendees.